Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms

I Ramasamy, M Brisco, A Morley

Abstract

Aims: To develop a simple, optimised, polymerase chain reaction (PCR) based method for detecting the rearranged immunoglobulin heavy chain (IgH).

Methods: Using as primers oligonucleotides (Fr2A, Fr2B) homologous to the conserved sequences to the framework II region and the joining (J_H) region, 25 patients with B cell lymphoproliferative disorders, previously characterised by Southern blotting, and three patients with light chain myeloma were studied.

Results: The PCR product from a polyclonal B cell population showed a broad band when analysed on a 3% agarose gel; DNA from B cell lines and B lymphoproliferative disorders showed a discrete band. Specificity of the amplification was confirmed by cloning and sequencing the amplified product as well as by Southern blotting with an internal probe homologous to the framework 3 region. Primers Fr2A and Fr2B detected monoclonality in three patients with light chain myeloma, while primers directed against the FrIII region showed a polyclonal response.

Conclusions: Deletions and extensive somatic mutations within the FrIII region may give false negative results with primers homologous to the region. A PCR using the method described, with a repertoire of primers homologous to the FrII and FrIII regions, will therefore increase the frequency of detection of monoclonality.

During the differentiation of B and T lymphocytes the rearrangement of the immunoglobulin and T cell receptor loci creates unique DNA sequences.¹ Such rearrangements are widely exploited as markers of B and T cell lineage and clonality in lymphoproliferative disorders.²

In B lymphocytes the variable region of the rearranged immunoglobulin heavy chain (V_H) contains three hypervariable complementary determining regions (CDRI, CDRII, CDRIII) and three relatively conserved framework regions (FrI, FrII, FrIII). Several investigators have developed methods to amplify rapidly the CDRIII region of the Ig heavy chain, using as primers oligonucleotides that have homology to the conserved sequences to the FrIII regions of the V_H gene segments and the 3' end of the J_H segments.³⁻⁵ Amplification with primers binding to the V_H and J_H region does not

proceed unless the gene is rearranged. Monoclonality in a B cell population is indicated by the production of a single discrete fragment following gel electrophoresis. The amplification product from a polyclonal population will result from a number of rearranged Ig genes, which will give rise to fragments of varying length, resulting in a broad band.

Primers complementary to the consensus regions have been developed from a limited number of IgH sequences and may not bind all possible V_H genes. Most studies with primers homologous to the framework III region report that amplification is detected in 75-80% of cases of B lymphoproliferative disorder.^{4,6} Compared with the FrIII, which is sufficiently conserved to enable the use of a single primer, a panel of seven different V_H family specific primers chosen from the FrI were required to detect Ig gene rearrangements in 94% of B lymphoid malignancies.⁷ The study with the FrI primers investigated 16 cases of B lymphoid malignancy but needs to be further investigated as a diagnostic technique, as polyclonal samples were not studied in detail.⁸

The failure of FrIII and FrI directed primers to detect IgH rearrangements in a significant percentage of B cell lymphoproliferative disorders may be due to somatic mutations within the FrI and FrIII regions. In a PCR reaction such mutations can cause a failure to prime with primers directed against these regions.

To overcome the problem of false negativity we have sought to develop an alternative, technically simple PCR based approach for detecting B lymphoid clonality in a routine laboratory setting, using oligonucleotides complementary to the FrII region and the J_H segment. The primers thus flank and amplify the CDRII, FrIII, and the CDRIII region. This study describes the development of the method and its use in detecting clonal IgH gene rearrangement in patients with light chain myeloma and other B lymphoproliferative disorders.

Methods

Patients with the following diseases were studied: acute lymphocytic leukaemia (ALL) $n = 9$; non-Hodgkin's lymphoma (NHL) $n = 7$; chronic lymphocytic leukaemia (CLL) $n = 4$; multiple myeloma (MM) $n = 5$; non-neoplastic lymph node enlargement $n = 2$. The patients had been previously classified by histology, cell surface markers, Southern hybridisation⁹ and by PCR with Fr3A/LJH as primers.⁶

Department of
Biochemistry,
Repatriation General
Hospital, Daws Road,
Daw Park, SA, 5041
Australia
I Ramasamy

Department of
Haematology, Flinders
Medical Centre,
Bedford Park,
Australia
M Brisco
A Morley

Correspondence to:
Dr I Ramasamy

Accepted for publication
23 March 1992

A further three patients with light chain myeloma were investigated:

Case A A 69 year old man presented with chronic renal failure (potassium 6.1 mmol/l, urea 26.4 mmol/l, creatinine 0.57 mmol/l, proteinuria for seven years). Agarose electrophoresis showed the presence of λ light chains in the urine.

Case B A 71 year old man, with a six month history of back pain and progressive lethargy. Electrolytes showed severe renal failure (creatinine 0.9 mmol/l, potassium 9.9 mmol/l). Lambda light chains were detected in the urine.

Case C A 70 year old man presented with anaemia, weight loss, immunoparesis and a raised ESR of 112 mm/hour (reference range < 23). Urine electrophoresis showed a dense band identified as κ light chains.

Monoclonal populations of non-neoplastic B lymphocytes were obtained by transforming mass populations of peripheral blood lymphocytes with Epstein Barr virus and then cloning at limiting dilutions. T lymphocytes were obtained by direct cloning of peripheral blood lymphocytes at limiting dilutions.¹⁰

DNA was extracted from peripheral blood (patients with ALL, CLL), lymph node (patients with NHL) or bone marrow (patients with MM, CLL), as described before¹¹ or by using the Applied Biosystems Nucleic Acid Extractor. Bone marrow specimens obtained at the time of diagnosis were available for cases A, B and C.

POLYMERASE CHAIN REACTION TO DETECT IG REARRANGEMENTS

(a) Primer design

Consensus primers termed Fr2A and Fr2B/Pst were designed from homologous regions within the framework region, and based on 17 published DNA sequences. These were chosen to bind and amplify any of the postulated 200–300 V_H segments.¹² The following strategy was used. If two bases occurred with equal frequency at a certain position, a redundancy of the two bases was introduced. If more than two occurred or if one predominated then the most frequently occurring base was included. To allow directed cloning of the amplified DNA, primers ELJH/Bam and Fr2B/Pst were constructed, with the indicated restriction site.

Primers were designed to be homologous to codons 36 to 42, and 37 to 47 respectively, of the framework 2 region.

Fr2A: 5' TGGA_GTCCGC_ACAGG_CCT_CT_T/CNGG 3' 20 base pairs

Fr2B/Pst: 5' GTCCTGCAGGCC_TC_TCCGGA_GAAA_GA_GGTCTGGAGTGG 3' 33 base pairs

Fr3A was designed from homologous regions within the framework 3 region, and covered codons 86 to 92.⁵

Fr3A: 5' ACACGGCC_TG_CTGTATTACTGT 3' 20 base pairs

To form the antisense strand, the six J_H germline sequences showed considerable homology¹³ to allow the design of primers LJH, VLJH, and ELJH.¹¹

LJH: 5' TGAGGAGACGGTGACC 3' 16 base pairs

VLJH: 5' GTGACCAGGGTNCCTTGGC-CCCAG 3' 24 base pairs

ELJH/Bam: 5' TGAGGAGACGGTGAC-CAGGATCCCTTGGCCAG 3' 34 base pairs

The primers are synthesised on the Applied Biosystems Nucleic Acid Synthesiser.

PCR conditions

The reactions were carried out in a volume of 25 μ l. The reaction mixture contained dATP, dCTP, dGTP, dTTP, primers, and template DNA in a buffer containing 10 mM β -mercaptoethanol, 67 mM TRIS (pH 8.8), 16.6 mM ammonium sulphate and 0.02% gelatin, 0.4 units of *Taq* polymerase (Cetus Corporation, 761 Main Ave, Norwalk, Connecticut 06859).

Reaction mixtures were covered with light mineral oil (Sigma Chemical Company, St Louis, Missouri 63178) to reduce evaporation. Amplified DNA was analysed by electrophoresis on 3% agarose in TBE buffer, 90 mM TRIS, 90 mM boric acid, and 2 mM EDTA. DNA was stained with ethidium bromide and visualised under short wave length ultraviolet light. PCR was carried out in a programmable heat block, the Perkin Elmer Thermocycler (Cetus Corporation).

Three primer combinations were used:

(I) *1st stage*: 1.0 mM of each dNTP, 4.5 mM Mg²⁺, 0.5 μ g of each primer Fr2A/LJH, with 1 μ g template DNA.

2nd stage: 0.24 mM of each dNTP, 2.0 mM Mg²⁺, 0.05 μ g of each primer Fr2A/VLJH, and a dilution of 1 in 5000 of 1st stage PCR product as DNA template.

Cycle conditions: Two minutes 94°C, two minutes 50°C, two minutes 72°C. Routinely 40 cycles were performed, with a five minute denaturation step at 94°C at the beginning of the reaction and 20 minute elongation step at the end.

(II) 0.5 mM of each dNTP, 2.0 mM Mg²⁺, 0.05 μ g of each primer Fr2B/ELJH, 100 or 200 ng template DNA.

Cycle conditions: One minute 94°C, one minute 60°C, one minute 72°C, for 45 cycles. A five minute denaturation at 94°C preceded the reaction and the last cycle included a 20 minute elongation period.

(III) PCR was performed as described by Trainor *et al.*¹¹ The PCR reaction mix contained 1 μ g DNA template, 100 ng of each primer Fr3A/LJH, with 0.1 mM of each dNTP and 2.0 mM MgCl₂. For the second round PCR, the product of the first amplification reaction was diluted 1 in 1000 and amplified in a 25 μ l reaction volume containing, 100 ng of each primer Fr3A/VLJH, 0.1 mM of each dNTP, 2.0 mM MgCl₂.

Cycle conditions: Five minutes denaturation at 94°C, followed by one minute at 60°C, one minute at 72°C and one minute at 94°C, for 30 cycles.

The electrophoresis of the PCR product was followed by blotting the gel on to a nitrocellu-

lose membrane, Hybond (Amersham International, plc). The hybridisation of the Southern blot with a kinase labelled internal ^{32}P -Fr3A probe was as described before.^{11 14}

DNA from one patient with multiple myeloma and one with non-Hodgkin's lymphoma was amplified using the primers Fr2B/Pst and ELJH/Bam, with the indicated restriction sites for directed cloning. The amplified product was cloned into the phage vectors M13mp18, M13mp19 phages and transformed into competent cells and sequenced by the dideoxy termination method, according to standard procedures.¹⁴

Results

OPTIMISATION OF THE PCR SYSTEM

The amplified DNA was expected to be 240–260 base pairs, and to include the CDRII,

CDRIII, and FrIII regions. The variation in base numbers reflected the differences in the N region and variation in V/D/J joins. Reaction parameters were empirically determined to yield the least amount of non-specific products and largest amount of specific products from six B lymphocyte cell lines. Under the same conditions, little or no PCR amplified products in the expected molecular weight range were generated from six T lymphocyte cell lines.

By increasing the stringency of the conditions, either by raising the temperature of annealing, decreasing the concentration of the primer, or optimising the magnesium concentration in relation to the total dNTP concentrations in the reaction mixture the yield of non-specific products was decreased. In further evaluation of the parameters it was found that increasing the length of the primers was advantageous as a similar specificity was achieved.

Figure 1 (A) Second stage amplification of patient DNA with Fr2A/VLJH.

Lane a: monoclonal response on a polyclonal background. Lanes b, d, h: monoclonal response. Lane c, e, f: polyclonal response. Lanes a–e: DNA from patients with ALL. Lane f: peripheral blood lymphocytes from healthy volunteer. Lane g: T cell line. Lane h: B cell line. Lane i: Control without DNA. Amplification was in duplicate. The arrow indicates molecular weight markers of 331 and 240 base pairs.

Figure 1 (B) PCR of DNA from different patients with Fr2B/ELJH as primers.

Lanes a, b, f, h: monoclonal response. Lanes c, d, e, g, j: polyclonal response. Lanes a–e: DNA from patients with ALL. Lane f: patient with myeloma. Lane g: non-neoplastic reactive lymph nodes. Lane h: B cell line. Lane i: T cell line. Lane j: peripheral blood lymphocytes from healthy volunteer. Lane k: control without DNA. Arrow indicates molecular weight markers of 331 and 240 base pairs.

ieved by a single amplification step. The most satisfactory amplifications were found with a single step PCR with primers Fr2B/ELJH and a two step PCR with primers Fr2A/LJH. Stringent conditions were therefore required for specific amplification of the rearranged IgH gene.

A specific band with the expected molecular weight of 240–260 base pairs was found in B cell lines as opposed to T cell lines, suggesting that amplification of the rearranged Ig gene found in B cell lines was achieved (figs 1A, B). Both T and B cell lines showed a non-specific amplification product of molecular weight 110 base pairs with the primer combination Fr2A/LJH, but this was not considered an interpretative problem in distinguishing cell lines with the rearranged and non-rearranged Ig genes. An end labelled 23 base pair internal probe Fr3A hybridised to the 240–260 base pair PCR product (data not shown). Cloning and sequencing of the amplified product from two patients, one with multiple myeloma (MM) and one with non-Hodgkin's lymphoma (NHL), further verified that the primers Fr2B/ELJH and Fr2A/LJH amplified the desired target sequences. A comparison of the sequence MM with the sequence V_{H-2} ¹⁵ of the V_H IV family showed an 85% homology, suggesting that the variable region of the heavy chain was formed from a germline sequence belonging to the V_H IV family and that the sequence MM probably used V_{H-2} as the germline sequence. If so, extensive somatic mutations had occurred in the CDRII region and base deletions had occurred around residue 89 during the formation of the V_H region. The sequence NHL shows some homology to previously published sequence 9(iii) + from the V_H III family,¹² but is most probably derived from a new germline sequence. The sequences of MM and NHL are available on request.

DETECTION OF MONOCLONAL B LYMPHOCYTE POPULATIONS

The result of a diagnostic run is shown in fig 1 (a, b). A sharp discrete band is taken as a monoclonal response, a diffuse band a polyclonal response. The gels were interpreted visually, the patient DNA samples were run in duplicate and for every 10 patient DNA samples a B and T cell line as well as DNA from the peripheral blood lymphocytes of a healthy volunteer and a negative control without DNA template were run as quality controls.

To assess the clinical validity of the method, 25 patients previously shown to be monoclonal by Southern blotting were studied. PCR with primers Fr2A/LJH detected monoclonal Ig

rearrangement in six of nine cases of ALL, three of four cases of B NHL, one of three cases of T NHL, four cases of CLL, and all five cases of MM. Monoclonality was also detected in all nine B cell lines, but not in nine T cell lines, in two patients with non-neoplastic reactive lymph nodes, and in polyclonal peripheral blood lymphocytes from seven healthy volunteers. The results of the double step PCR with Fr2A/LJH and a single step amplification step with Fr2B/ELJH were similar, except for a single patient with MM who showed a monoclonal response with Fr2A/LJH alone.

A comparison of PCR with the FrII primers with published techniques^{9,6} showed that primers Fr2A/2B detected monoclonality in the tumours of 18 out of 19 patients previously classified as monoclonal with Fr3A/VLJH and Southern blotting, but one case of B NHL failed to show monoclonality. There were three patients with ALL who showed detectable monoclonal IgH rearrangement by Southern blotting but were negative with primers directed against either FrII or FrIII regions. Three patients with T NHL who did not show IgH gene rearrangement by Southern blotting were negative with both the FrII and FrIII primers. False positive results were therefore not detected.

DETECTION OF THE REARRANGED IGH GENES IN LIGHT CHAIN MYELOMA

The advantages of the new technique were investigated in a study of three patients with light chain myeloma. The table shows that at diagnosis, the double step PCR with Fr2A/LJH yielded positive results with all three patients (figs 2A, B), but one patient showed a positive result with Fr2B/ELJH. IgH rearrangement was not detected in all three patients with the primer pairs Fr3A/VLJH.

DNA from the peripheral blood samples from cases A and B, taken at the same time, showed a polyclonal response, though a minor degree of monoclonality was detected in case B (fig 2A). In a single case (fig 2A) two heavy chain Ig gene rearrangements were observed, suggesting at least one abortive VDJ join had occurred.

Discussion

We developed a PCR technique for the analysis of B lymphoid clonality. The technique relies on the detection of Ig heavy chain VDJ rearrangement by using consensus primers against the framework II and the J regions of the Ig gene. The amplified product was confirmed to be the IgH gene, as it hybridised to an internal V_H probe, and when sequenced contained typical VDJ rearrangements.

The FrII primers showed a monoclonal response in 18 of 22 patients shown to have clonal IgH rearrangements by Southern blotting. Similarly, 18 of 19 patients with a monoclonal response shown by FrIII primers were positive by the FrII primers. Both sets of primer combinations, Fr2A/VLH and Fr2B/ELJH, gave similar results. In one patient with

Detection of rearranged IgH gene from three light chain myeloma patients

Case No	Fr2A/VLJH	Fr2B/ELJH	Fr3A/VLJH	Bone marrow report
A	M	M	P	40% of nucleated cells, plasma cells
B	M	P	P	50% of nucleated cells, plasma cells
C	M	P	P	59% of nucleated cells, plasma cells

DNA was extracted from bone marrow at diagnosis and tested with the indicated primer pairs. M = monoclonal response; p = polyclonal response.

Figure 2A PCR analysis of Ig rearrangement from case B, with light chain myeloma, with Fr2A/VLJH as primers. Lane a: bone marrow from case B. Lane b: peripheral blood lymphocytes from case B. Lane c: peripheral blood lymphocytes from healthy volunteer. Lane d: control without DNA. Lane e: T cell line. Lane f: B cell line. Lanes a and f show a monoclonal response. Arrow indicates molecular weight markers of 331 and 240 base pairs.

Figure 2B PCR analysis of Ig rearrangement from case A, with light chain myeloma, with Fr2B/ELJH as primers. Lane a: bone marrow from case A. Lane b: peripheral blood lymphocytes from case B. Lane c: peripheral blood lymphocytes from a healthy volunteer. Lane d: bone marrow from patient with mm. Lane e: peripheral blood lymphocytes from patient with mm. Lane f: control without DNA. Lane g: T cell line. Lane h: B cell line. Lanes a, d, and h show a monoclonal response. Lanes d and e are from a different PCR run and are included for comparison. Arrow indicates molecular weight markers of 331 and 240 base pairs.

MM monoclonality was detected by PCR with Fr2a/VLJH, Fr3A/VLJH, and Southern blotting, but not with Fr2B/ELJH. Possible explanations for this could be suboptimal priming by the longer primers, or the greater sensitivity of the two step PCR over the technically more convenient one stage method. In this study four out of 21 patients did not show a monoclonal band despite detection of Ig heavy chain rearrangement by Southern blotting. It may be that primers complementary to the consensus region of the framework sections may not bind all of the postulated 200–300 V_H segments,¹² or that Southern blotting detected D-J rearrangement that did not proceed to a VDJ joining, or that the J_H segment was involved in an unusual gene translocation.

In B cell maturation the rearrangement of heavy chain genes precedes that of the light chain genes.¹⁶ Using Southern blotting and a J_H probe clonal, heavy chain rearrangements have been found in the bone marrow of patients with pure Bence Jones myeloma.¹⁷

Using the polymerase chain reaction we have confirmed that rearrangements of the VDJ regions occur in tumours that secrete light chains alone. Alterations in transcription controlling elements¹⁸ or mRNA splicing signals¹⁹ can prevent the formation of a functional heavy chain protein, but at this stage it is difficult to know whether the heavy chain rearrangement is transcriptionally silent or simply defective. Heavy chain expression was, however, not detected by immunoprecipitation with anti-human heavy chain antisera in two κ secreting myeloma cell lines SKMM1 and SKMM2.²⁰

Heavy chain gene rearrangements in light chain myeloma patients were not detected by the Fr3A/VLJH primer combination. This may indicate a defect in the 3' end of the V_H segment. Deletion of part of the FrIII primer binding region has been observed in three out of 36 patients with ALL when the PCR amplified product was sequenced (Condon J, Hughes E, Brisco M, unpublished observations). Deane *et al* report four cases of B NHL

that were negative for PCR amplification of the IgH gene with an FrIII primer.⁸ On further investigation of two of these patients a 24% mismatch with a FrIII primer, which included a mismatch within the 3' terminal bases of the primer, was identified. In such cases the primer Fr3A will anneal poorly and stable priming duplexes with the V_H oligonucleotide will not be formed.

In some cases of leukaemia and lymphomas lineage and clonality may be difficult to determine using immunophenotypic methods. Studies have shown that analysis of gene rearrangements can resolve such diagnostic problems.²⁻²¹ PCR is preferred to Southern blotting which is technically more complex, requires a larger amount of DNA, and is time consuming. The PCR technique can be widely applied in that it has also been successfully used for surgical biopsy⁴ and paraffin wax embedded sections,²² and node aspirates.⁶

The present technique has implications for the available strategies for the detection of minimal residual disease. Primers consensus to the FrIII and the J_H region have been used to amplify the CDRIII region. The CDRIII region, thus amplified, is unique to each IgH rearrangement, and is used to generate either diagnostic oligonucleotide probes³⁻²³ or PCR primers⁵ that do not cross hybridise with the CDRIII sequences of the normal B lymphocyte. Using such CDRIII probes residual leukaemic disease can be successfully detected in patients with B cell lineage malignancies.²⁴ Our technique increases the scope for the design of leukaemia specific oligonucleotides as it permits the sequencing of CDRII, a second hypervariable region.

The methods for detecting monoclonality that rely on consensus sequences to the framework III regions have the disadvantage that 20–30% of B cell neoplasms are not detected⁴⁻¹⁰ or that efficiency of amplification of individual leukaemic alleles was highly variable.²⁴ Similarly, the PCR technique, which relies on primers directed against the FrI region, has the disadvantage that a panel of seven different primers is required.⁷ Previous investigators have suggested that better primers may overcome the problem of false negative results, thus increasing the diagnostic value of the test.⁶

In summary, our PCR gene amplification procedure describes an approach that has the advantage of detecting IgH rearrangement which may involve unusual rearrangements in the 3' region of the V_H gene, and therefore not be amplified by primers binding to the FrIII region. In general, it is advisable to use a repertoire of primers homologous to the various framework regions to avoid the risk of false negative results. This approach increases the reliability of the detection of clonal IgH gene rearrangements as equivocal results with primers directed against a single framework

region can be further evaluated by primers consensus to the other two framework regions. Such studies may also be useful in elucidating the pathogenesis of B cell lymphoproliferative disorders.

- 1 Tonegawa S. Somatic generation of antibody diversity. *Nature* 1987;30:575–81.
- 2 Arnold A, Crossman J, Bakshi A, Jaffe ES, Waldmann TA, Korsmeyer SJ. Immunoglobulin gene rearrangements as unique clonal markers in human lymphoid neoplasm. *N Engl J Med* 1983;309:1593–9.
- 3 Yamada M, Hudson S, Tournay O, et al. Detection of minimal disease in haematopoietic malignancies of the B cell lineage by using the third complementary-determining region CDRIII specific probes. *Proc Natl Acad Sci USA* 1989;86:5123–7.
- 4 McCarthy KP, Sloane JP, Wiedemann CM. Rapid method for distinguishing clonal from polyclonal B cell populations in surgical biopsy specimens. *J Clin Pathol* 1990;43:429–32.
- 5 Brisco MJ, Tan LW, Orsborn AM, Morley AA. Development of a highly sensitive assay based on the polymerase chain reaction for rare B lymphocyte clones in a polyclonal population. *Br J Haematol* 1990;75:163–7.
- 6 Trainor KJ, Brisco MJ, Wan JH, Neoh S, Grist S, Morley AA. Gene rearrangements in B and T lymphoproliferative disease detected by the polymerase chain reaction. *Blood* 1991;78:192–6.
- 7 Deane M, Norton JD. Immunoglobulin gene fingerprinting: an approach to the analysis of B lymphoid clonality in lymphoproliferative disorders. *Br J Haematol* 1991;77:274–81.
- 8 Deane M, McCarthy KP, Wiedemann LM, Norton JD. An improved method for the detection of B lymphoid clonality by polymerase chain reaction. *Leukemia* 1991;5:726–30.
- 9 Story CJ, Morley AA, Turner PR, Seshadri R. Diagnostic use of immunoglobulin and T cell receptor gene rearrangements in lymphoproliferative disease. *Aust NZ J Med* 1987;17:1–9.
- 10 Morley AA, Trainor KJ, Seshadri R. Cloning of human lymphocytes using limiting dilution. *Exp Haematol* 1983;11:418–21.
- 11 Trainor KJ, Brisco MJ, Story CJ, Morley AA. Monoclonality in B lymphoproliferative disorders detected at the DNA level. *Blood* 1990;75:2220–2.
- 12 Berman JE, Scott JM, Bollock R, et al. Content and organisation of the human Ig V_H families and linkage to the Ig C_H locus. *Embo J* 1988;7:727–38.
- 13 Ravetch JV, Siebenlist U, Korsmeyer S, Waldmann T, Leder P. Structure of the immunoglobulin locus: characterisation of embryonic and rearranged J and D genes. *Cell* 1981;27:583–91.
- 14 Miniatis T, Fritsch EF, Sambrook J. *Molecular cloning: a laboratory manual*. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1982.
- 15 Lee KH, Matsuda F, Kinashi T, Kodaira M, Honjo T. A novel family of variable region genes of the human immunoglobulin heavy chain. *J Mol Biol* 1987;195:761–8.
- 16 Alt FW, Yancopoulos GD, Blackwell TK, et al. Ordered rearrangement of immunoglobulin heavy chain variable region segments. *Embo J* 1984;3:1209–16.
- 17 Clofert G, Klein B, Commes T, Gihanem N, Lefranc MP, Bataille R. No detectable malignant B cells in the peripheral blood of patients with multiple myeloma. *Br J Haematol* 1989;71:357–61.
- 18 Grosschedl R, Baltimore D. Cell type specificity of Ig gene expression is regulated by three DNA sequence elements. *Cell* 1985;41:885–97.
- 19 Yancopoulos GD, Alt FW. Regulation of the assembly and expression of variable region genes. *Ann Rev Immunol* 1986;4:339–68.
- 20 Eton O, Scheiberg DA, Houghton AN. Establishment and characterisation of two human myeloma cell lines secreting kappa light chains. *Leukemia* 1989;3:729–35.
- 21 Lardell P, Swaby RF, Medeiros CJ, Jaffe ES, Rissl R, Stettler-Stevenson M. Determination of lineage and clonality in diffuse lymphomas using the polymerase chain reaction technique. *Hum Pathol* 1991;22:685–9.
- 22 Wan JH, Trainor KJ, Brisco MJ, Morley AA. Monoclonality in B cell lymphoma detected in paraffin wax embedded sections using the polymerase chain reaction. *J Clin Pathol* 1990;43:888–90.
- 23 Jonsson OG, Kitchens RL, Scott FC, Graham Smith R. Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes. *Blood* 1991;76:2072–9.
- 24 Yamada M, Wasserman R, Lange B, Relchard B, Womer RB, Rover GF. Minimal residual disease in childhood B lineage lymphoblastic leukemia. *N Engl J Med* 1990;323:448–55.